Altitude Lab Startups Raise $154M in Capital
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones
In addition,
“Elnora AI is capturing real-world experimental data directly from academic researchers—positive, negative, and everything in between. This enables our AI-powered lab protocol optimizer, helping researchers get their experiments working faster while building the most comprehensive dataset for drug discovery,” said Kivisild. “The Gibson Fellowship gave us critical funding and an anchor community as we relocated from
Applications for the 2025 Gibson Founder Fellowship are now open.
“In 2025, we anticipate a wave of Series A funding rounds from our alumni and broader founder community,” said
Key Milestones from Altitude Lab’s Portfolio:
- 19 startups in Altitude Lab’s current cohort and 12 alumni
- 70% of startups are led by at least one underrepresented founder
- 90% of all participating startups have raised capital
- Peel Therapeutics completed a Phase 1 trial for its PEEL-224 TOP1 inhibitor and closed the first tranche of its Series A
- Rebel Medicine received IND approval for Alevatrix and closed the first tranche of its Series A
- Sethera established Dr.
Robert Langer ,MIT faculty and co-founder of Moderna, as chair of theirScientific Advisory Board - Teiko launched a 25-marker spectral flow cytometry assay on fixed whole blood, combining high-throughput immune measurement of ~150 populations with extended stability for global clinical trials.
Applications to join Altitude Lab’s newest cohort are now open. Learn more and apply for residency and the Founder Fellowship at altitudelab.org.
About Altitude Lab
Learn more at altitudelab.org or connect on X.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in

Media Contact Media@Recursion.com Investor Contact Investor@Recursion.com
Recursion Pharmaceuticals